Hazards of thrombolytic therapy in XXXX .

@entity1150 @entity1 @entity548 @entity1151
From 1965 to 1985, 64 @entity1150 ( @entity1150 ) @entity1 were treated with streptokinase (SK). In 26 cases 'high-dose SK' (IV 100,000 units/h for 4 days) was used and in 38 @entity1 a 'low-dose SK' regime (IV 250,000 units every 12 h for 4 days) was employed. The clinical signs of @entity1150 subsided in 78 per cent of treated @entity1 within 30 days of completing SK treatment. A repeat phlebography was performed immediately after SK therapy in 29 @entity1 (45 per cent) and a total recanalization or partial thrombolysis was achieved in 80 per cent of the studied cases. In 15 @entity1 minor and major @entity548 occurred. There were five fatalities, all in the high-dose SK group (three intracranial @entity548 and two major @entity548 ). Three @entity1 developed @entity1151 and none of them died. The post-treatment clinical and phlebographic evaluation did not reveal any significant difference between the two methods of SK administration, but more @entity548 (P less than 0.02, chi=5.50825) occurred in the high-dose SK @entity1 . This report emphasizes the risk of @entity548 complications during thrombolytic therapy. If SK is to be used, therefore, careful selection of @entity1 and meticulous monitoring are mandatory.
